KR101827444B1 - 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 - Google Patents

트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 Download PDF

Info

Publication number
KR101827444B1
KR101827444B1 KR1020120010465A KR20120010465A KR101827444B1 KR 101827444 B1 KR101827444 B1 KR 101827444B1 KR 1020120010465 A KR1020120010465 A KR 1020120010465A KR 20120010465 A KR20120010465 A KR 20120010465A KR 101827444 B1 KR101827444 B1 KR 101827444B1
Authority
KR
South Korea
Prior art keywords
acid
morpholinomethyl
ethoxy
tetrahydrobenzo
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120010465A
Other languages
English (en)
Korean (ko)
Other versions
KR20130089089A (ko
Inventor
김명화
예인해
박준호
최종희
강동일
Original Assignee
제일약품주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제일약품주식회사 filed Critical 제일약품주식회사
Priority to KR1020120010465A priority Critical patent/KR101827444B1/ko
Priority to MX2014009168A priority patent/MX346794B/es
Priority to PCT/KR2013/000676 priority patent/WO2013115535A1/ko
Priority to RU2014131888/04A priority patent/RU2572820C1/ru
Priority to BR112014018763-0A priority patent/BR112014018763B1/pt
Publication of KR20130089089A publication Critical patent/KR20130089089A/ko
Priority to US14/338,923 priority patent/US9522911B2/en
Application granted granted Critical
Publication of KR101827444B1 publication Critical patent/KR101827444B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/02—Formic acid
    • C07C53/06—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020120010465A 2012-02-01 2012-02-01 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법 Active KR101827444B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020120010465A KR101827444B1 (ko) 2012-02-01 2012-02-01 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
MX2014009168A MX346794B (es) 2012-02-01 2013-01-28 Nuevas sales cristalinas de adicion de acido de derivado triciclico o hidruro del mismo y metodo de produccion de las mismas.
PCT/KR2013/000676 WO2013115535A1 (ko) 2012-02-01 2013-01-28 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법
RU2014131888/04A RU2572820C1 (ru) 2012-02-01 2013-01-28 Новые кристаллические кислотно-аддитивные соли трициклического производного или их гидраты и способ их получения
BR112014018763-0A BR112014018763B1 (pt) 2012-02-01 2013-01-28 Sais de adição de ácido cristalino de um derivado tricíclico ou hidratos dos mesmos e método de produção dos mesmos
US14/338,923 US9522911B2 (en) 2012-02-01 2014-07-23 Crystalline forms of tricyclic compound acid salt or hydrate thereof, and method for making thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120010465A KR101827444B1 (ko) 2012-02-01 2012-02-01 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법

Publications (2)

Publication Number Publication Date
KR20130089089A KR20130089089A (ko) 2013-08-09
KR101827444B1 true KR101827444B1 (ko) 2018-02-08

Family

ID=48905516

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120010465A Active KR101827444B1 (ko) 2012-02-01 2012-02-01 트리사이클로 유도체 화합물의 신규한 결정형 산부가염 또는 이의 수화물 및 이의 제조방법

Country Status (6)

Country Link
US (1) US9522911B2 (cg-RX-API-DMAC7.html)
KR (1) KR101827444B1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018763B1 (cg-RX-API-DMAC7.html)
MX (1) MX346794B (cg-RX-API-DMAC7.html)
RU (1) RU2572820C1 (cg-RX-API-DMAC7.html)
WO (1) WO2013115535A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3312177T (pt) 2015-06-09 2021-05-17 Onconic Therapeutics Inc Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo
KR20180062804A (ko) * 2016-12-01 2018-06-11 사회복지법인 삼성생명공익재단 트리시클릭 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 허혈성 급성 신손상 예방 또는 치료용 약학적 조성물
EP4063358B1 (en) 2016-12-22 2024-05-22 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
JP2022551373A (ja) * 2019-07-29 2022-12-09 ジェイル ファーマシューティカル カンパニー リミテッド 三環式誘導体を用いた脳卒中の治療方法
CN114249735A (zh) * 2020-09-25 2022-03-29 江西青峰药业有限公司 一种parp抑制剂中间体晶型及其制备方法和应用
KR20220149268A (ko) * 2021-04-30 2022-11-08 주식회사 온코크로스 트리사이클로 유도체 화합물을 포함하는 대사질환 예방 또는 치료용 조성물
CA3219303A1 (en) * 2021-05-18 2022-11-24 Onconic Therapeutics Inc. Crystalline form of tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696437B1 (en) 1999-05-07 2004-02-24 Abbott Gmbh & Co. Kg Heterocyclically substituted benzimidazoles, the production and application thereof
US20040067949A1 (en) 2000-05-11 2004-04-08 Roland Grandel Substituted indoles which are parp inhibitors
US20050074470A1 (en) 1999-09-01 2005-04-07 Guilford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2364983T3 (pl) * 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696437B1 (en) 1999-05-07 2004-02-24 Abbott Gmbh & Co. Kg Heterocyclically substituted benzimidazoles, the production and application thereof
US20050074470A1 (en) 1999-09-01 2005-04-07 Guilford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US20040067949A1 (en) 2000-05-11 2004-04-08 Roland Grandel Substituted indoles which are parp inhibitors

Also Published As

Publication number Publication date
BR112014018763A2 (cg-RX-API-DMAC7.html) 2017-06-20
MX2014009168A (es) 2014-08-27
RU2572820C1 (ru) 2016-01-20
WO2013115535A1 (ko) 2013-08-08
BR112014018763A8 (pt) 2017-07-11
US9522911B2 (en) 2016-12-20
KR20130089089A (ko) 2013-08-09
BR112014018763B1 (pt) 2022-08-02
US20140350007A1 (en) 2014-11-27
MX346794B (es) 2017-03-31

Similar Documents

Publication Publication Date Title
AU2021209257B2 (en) Bicyclic BET bromodomain inhibitors and uses thereof
CN112745335B (zh) 一种三并杂环化合物及其用途
KR102499780B1 (ko) Fgfr4 저해제인 헤테로 고리 화합물
CN104945375B (zh) 7‑{(3s,4s)‑3‑[(环丙基氨基)甲基]‑4‑氟吡咯烷‑1‑基}‑6‑氟‑1‑(2‑氟乙基)‑8‑甲氧基‑4‑氧‑1,4‑二氢喹啉‑3‑羧酸晶体
US9522911B2 (en) Crystalline forms of tricyclic compound acid salt or hydrate thereof, and method for making thereof
CN112707905B (zh) 一种三并杂环化合物及其制备方法和用途
TW202023561A (zh) 抗菌化合物
CN112142747B (zh) 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN113454082A (zh) 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途
CA3179059A1 (en) Collagen 1 translation inhibitors and methods of use thereof
US11827640B2 (en) Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators
AU2013323206A1 (en) Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2024050370A1 (en) Heterocyclic compounds and methods of use thereof
JP2024545244A (ja) テトラヒドロピリダジン、それらを含む組成物およびその使用
CN114685520B (zh) 三并环化合物及其药物组合物和应用
WO2011078226A1 (ja) 三環系化合物
JP2018501282A (ja) チアゾール誘導体の製造方法
CN113840605A (zh) N-(5-((4-乙基哌嗪-1-基)甲基)吡啶-2-基)-5-氟-4-(3-异丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其盐的结晶和无定形形式,及其制备方法和治疗用途
JP7759380B2 (ja) スルホニル尿素環置換化合物の塩形および結晶形
KR101098031B1 (ko) 암로디핀 니코티네이트의 신규 결정형 및 이의 제조방법
CN106132972B (zh) 用于治疗hcv感染的氨基磷酸酯
CN115724846A (zh) 异喹啉磺酰衍生物新晶型及其制备方法和用途
CN119866332A (zh) 铁死亡抑制剂-吩噁嗪乙酰胺
JPWO2002088147A1 (ja) セフェム化合物の硫酸塩
CN117321054A (zh) 三环衍生物化合物的结晶形式、制备其的方法和包含其的药物组合物

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20120201

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160617

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20120201

Comment text: Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20170627

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170807

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180102

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170807

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180102

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170929

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20180201

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180108

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180102

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20170929

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20180202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20180205

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20210113

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240117

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20250121

Start annual number: 8

End annual number: 8